Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Human GH or placebo and GnRH-a were administered SC; gonadotropin was administered IM.

Oocytes were collected by ultrasound-guided transvaginal aspiration of follicles.

Embryos were cultured in vitro and transferred transcervically.

What Was Measured

PubMed files the paper under topics including Clinical Protocols, Fertilization in Vitro, Gonadotropin-Releasing Hormone, Growth Hormone, Infertility, Female, Insulin-Like Growth Factor Binding Protein 1 and Insulin-Like Growth Factor Binding Protein 3.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1996 (Fertility and sterility), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.